{"id":484820,"date":"2020-05-15T19:20:01","date_gmt":"2020-05-15T19:20:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=484820"},"modified":"2020-05-15T19:20:01","modified_gmt":"2020-05-15T19:20:01","slug":"acute-kidney-injury-pipeline-analysis-emerging-therapies-that-shall-drive-the-market-ahead","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-kidney-injury-pipeline-analysis-emerging-therapies-that-shall-drive-the-market-ahead_484820.html","title":{"rendered":"Acute Kidney Injury Pipeline Analysis: Emerging therapies that shall drive the market ahead"},"content":{"rendered":"
\"Acute<\/a><\/p>\n
\n
Acute Kidney Injury Pipeline Analysis <\/div>\n<\/div>\n<\/div>\n
Key players such as ANG-3777 (BB3; Angion Biomedica), QPI1002 (Quark Pharmaceutical), ASP1128 (Astellas Pharma), MB-102 (MediBeacon), Ruconest (Conestat alfa; PharmingTechnologies), recAP (AM Pharma), bRESCAP (Alloksys), Reltecimod (Atox Bio), EA-230 (Exponential Biotherapies) and Simdax (Levosimendan; Orion Pharma) are working robustly to bring these emerging therapies in the market for the patients with Acute Kidney Injury.<\/div>\n

“Acute Kidney Injury (AKI) Pipeline Insight, 2020<\/a><\/strong>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Kidney Injury (AKI) market. A detailed picture of the Acute Kidney Injury (AKI) pipeline landscape is provided, which includes the disease overview and Acute Kidney Injury (AKI) treatment guidelines.<\/p>\n

The assessment part of the report embraces in-depth Acute Kidney Injury (AKI) commercial assessment and clinical assessment of the Acute Kidney Injury (AKI) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Kidney Injury (AKI) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

At present, there are no targeted pharmacotherapies approved for the treatment of AKI.<\/strong> At present, the therapeutic market size of Acute Kidney Injury in the United States is mainly accounted by use of Renal Replacement Therapy (RRT) and off-label drugs which include various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).<\/p>\n

However, robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of Acute Kidney Injury market. Additionally, the Acute Kidney Injury pipeline is also expected to change the current dynamics of market which presently comprises of Biologics and molecules with new mechanisms of action.<\/p>\n

In the Pipeline and key companies <\/strong><\/p>\n

The Acute Kidney Injury pipeline<\/strong> possesses several potential products that are being developed in different stages of clinical development. Key players such as ANG-3777<\/strong> (BB3; Angion Biomedica), QPI1002<\/strong> (Quark Pharmaceutical), ASP1128<\/strong> (Astellas Pharma), MB-102<\/strong> (MediBeacon), Ruconest<\/strong> (Conestat alfa; PharmingTechnologies), recAP<\/strong> (AM Pharma), bRESCAP<\/strong> (Alloksys), Reltecimod<\/strong> (Atox Bio), EA-230<\/strong> (Exponential Biotherapies) and Simdax<\/strong> (Levosimendan; Orion Pharma) are working robustly to bring these emerging therapies in the market for the patients with Acute Kidney Injury.<\/p>\n

Out of these emerging key players, Angion Biomedica<\/strong> and Quark Pharmaceuticals<\/strong> are expected to launch promising therapies in their respective target population pool.<\/p>\n

Visit to know more.<\/a><\/strong><\/p>\n

As per DelveInsight, Acute Kidney Injury Market Size in the 7 MM was observed to be USD 4,082.95 Billion in 2017, which is expected to increase by 2030 significantly. <\/strong><\/p>\n

Scope of the report<\/strong><\/p>\n